Business

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

Financial Post · August 28, 2026 at 6:45 p.m.

OSAKA, Japan & CAMBRIDGE, Mass. -- Takeda ( TSE:4502/NYSE:TAK ) announced U.S.

Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer.

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

More from Financial Post

Hypercharge Reports First Quarter Fiscal 2027 Results & Management Change

Sable Announces Grant of Options

News of the day: Canada’s GDP grows, Ottawa invests in Xanadu, the Warsh effect, the price of wrongful dismissal, saving tax on your portfolio and more

Central 1 reports second quarter 2026 financial results

More in Business

Hypercharge Reports First Quarter Fiscal 2027 Results & Management Change

Sable Announces Grant of Options

News of the day: Canada’s GDP grows, Ottawa invests in Xanadu, the Warsh effect, the price of wrongful dismissal, saving tax on your portfolio and more

Central 1 reports second quarter 2026 financial results

Traction Uranium Announces Closing of Non-Brokered Flow-Through Private Placement

Matador Technologies Receives TSX Venture Exchange Conditional Approval for Proposed Creation of a New Class of Preferred Shares